Limited Financial Effect

The program proves to be mostly a targeted employee-benefit announcement with limited earnings implications. Investors treat the plan as manageable because the covered medicines are largely high-volume, lower-cost generics for common conditions.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.